Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saye Khoo

Showing results (141-150 of 282) with videos related to

Pageof 29
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenTim R Cressey, Hannah Green, Saye Khoo, et al.
Frontiers in Pharmacology|February 14, 2022
PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver DiseaseMaiara Camotti Montanha, Nicolas Cottura, Michael Booth, et al.
AIDS Research and Human Retroviruses|October 31, 2003
Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boostingMarta Boffito, Stefano Bonora, Paola Sales, et al.
BMC Health Services Research|August 3, 2020
Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and UgandaYussif Alhassan, Adelline Twimukye, Thoko Malaba, et al.
The Journal of Antimicrobial Chemotherapy|December 12, 2018
Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolitesEric H Decloedt, Phumla Z Sinxadi, Gert U van Zyl, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2020
Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokineticsEmilie R Elliot, Megan Neary, Laura Else, et al.
British Journal of Clinical Pharmacology|November 25, 2018
Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?Sa'ad T Abdullahi, Adeniyi Olagunju, Julius O Soyinka, et al.
The Journal of Antimicrobial Chemotherapy|April 15, 2022
Removal of doravirine by haemodialysis in people living with HIV with end-stage renal diseaseJosé Moltó, Fredzzia Graterol, Adrian Curran, et al.
BMC Public Health|December 8, 2020
Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and UgandaYussif Alhassan, Adelline Twimukye, Thoko Malaba, et al.
AIDS (London, England)|April 7, 2007
Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudyBen Kikaire, Saye Khoo, A Sarah Walker, et al.
Pageof 29

Showing results (141-150 of 282) with videos related to

Sort By:
Pageof 29
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenTim R Cressey, Hannah Green, Saye Khoo, et al.
Frontiers in Pharmacology|February 14, 2022
PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver DiseaseMaiara Camotti Montanha, Nicolas Cottura, Michael Booth, et al.
AIDS Research and Human Retroviruses|October 31, 2003
Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boostingMarta Boffito, Stefano Bonora, Paola Sales, et al.
BMC Health Services Research|August 3, 2020
Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and UgandaYussif Alhassan, Adelline Twimukye, Thoko Malaba, et al.
The Journal of Antimicrobial Chemotherapy|December 12, 2018
Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolitesEric H Decloedt, Phumla Z Sinxadi, Gert U van Zyl, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2020
Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokineticsEmilie R Elliot, Megan Neary, Laura Else, et al.
British Journal of Clinical Pharmacology|November 25, 2018
Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?Sa'ad T Abdullahi, Adeniyi Olagunju, Julius O Soyinka, et al.
The Journal of Antimicrobial Chemotherapy|April 15, 2022
Removal of doravirine by haemodialysis in people living with HIV with end-stage renal diseaseJosé Moltó, Fredzzia Graterol, Adrian Curran, et al.
BMC Public Health|December 8, 2020
Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and UgandaYussif Alhassan, Adelline Twimukye, Thoko Malaba, et al.
AIDS (London, England)|April 7, 2007
Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudyBen Kikaire, Saye Khoo, A Sarah Walker, et al.
Pageof 29